

February 12, 2016

## **Exchange Notice**

## Flexible Derivatives Products 02/16

## Anticipated adjustment in Karo Bio due to rights issue

The following information is based on a press release from Karo Bio AB (Karo Bio) published on February 12, 2016 and may be subject to change.

The board of Karo Bio has proposed that the Extra General Meeting (EGM), scheduled for March 16, 2016, approves a rights issue whereby shareholders are entitled to one (1) new share for every four (4) shares held. The subscription price is SEK 20.00 per share. The scheduled Ex-date is March 22, 2016. Provided that the EGM approves the rights issue, NASDAQ Derivatives Markets will carry out a recalculation of options, forwards and futures in Karo Bio (KAROB).

## Re-calculation of stock options, forwards and futures

Conditions	Rights issue, 1:4, SEK 20.00 per share			
Ex-date	March 22, 2016			
Adjustment factor <sup>1</sup>	$A = \frac{Number\ of\ shares\ prior\ to\ the\ offer}{Number\ of\ shares\ after\ the\ offer} * \left[1 - \frac{Issue\ price}{VWAPcum}\right] + \frac{Issue\ price}{VWAPcum}$			
New exercise and forward/future price	Old exercise and forward/future price * A			
New contract size	Old contract size / A			
Date of re-calculation	After 19.30 (CET), March 21, 2016			
Rules and Regulations of NASDAQ Derivatives Markets	3.5.3.4			

<sup>1</sup> VWAPcum = volume weighted average price at the bank day prior to the ex-day (8 decimals are used)

Following an adjustment the number of shares per contract will increase, whereas exercise and forward/future prices will decrease. Further information regarding the re-calculation of the options, forwards and futures contracts will be published in connection with the adjustment.

Members are encouraged to ensure that clients are aware of the above-mentioned adjustment.



For further information con-	cerning this exchange	notice please co	ntact Elisabeth	Mastrovito or	Tomislav
Blazevic, telephone +46 8 4	105 60 00.				

NASDAQ Derivatives Markets

Elisabeth Mastrovito Product Management Tomislav Blazevic Product Management